Congressman John Shimkus

Representing the 15th District of Illinois


Crucial Antibiotics Bill Reintroduced

Jun 4, 2015
Press Release

WASHINGTON – On May 21, the House Energy and Commerce Committee held a markup of H.R. 6, the 21st Century Cures Act and voted the bill out of committee unanimously. This legislation included the widely heralded ADAPT Act (sections 2121-2122), championed by Representatives Gene Green (D-TX) and John Shimkus (R-IL), to establish a streamlined approval pathway for the development and approval of the next generation of antibiotics. Today, Shimkus and Green introduced, H.R. 2629, the Antibiotic Development to Advance Patient Treatment or ADAPT  Act as a free standing bill to highlight support for this important provision.

“I am proud to be joined by my colleagues on the Energy and Commerce Committee on both sides of the aisle and health policy leaders in support of this critical legislation,” Green said.  “Addressing the lack of treatments for drug-resistant infections unites us above partisan, geographic and ideological differences. Without greater investment in new treatments, we face a future that resembles a pre-antibiotic era.”

Shimkus said, “The 21st Century Cures Act is a testament to what we can accomplish when we work together. I’m pleased this landmark legislation includes our provision to address the growing threat posed by antibiotic resistant infections. By also introducing the ADAPT Act as a standalone bill, our colleagues will now have the opportunity to register their explicit support for this critical provision of the 21st Century Cures Act.”

The ADAPT Act will advance antimicrobial development in order to combat the dire public health threat of “superbugs,” which the Center for Disease Control (CDC) warned of early last year. This language would accelerate the development of innovative treatments by creating a new pathway for antibiotics and antifungals aimed at treating drug-resistant infections in patients with an unmet medical need.

The 21st Century Cures Act was voted out of Committee unanimously with a vote of 51-0. It is expected to come before the full House for a vote this month.